remacemide

Remacemide is a small molecule drug that acts as a low-affinity, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor and also blocks voltage-dependent neuronal sodium channels. It was developed primarily for neuroprotective indications associated with glutamate-mediated neurotoxicity. Remacemide and its active metabolite AR-R 12495 AR have shown efficacy in animal models of epilepsy, Parkinson's disease, Huntington's disease, and acute ischemic stroke. Clinical studies demonstrated modest effects on seizure frequency in epilepsy and some trends toward improvement in motor fluctuations in Parkinson’s disease when used as adjunct therapy to levodopa. However, due to limited efficacy and dose-related adverse events such as dizziness and gastrointestinal disturbances, development for these indications has been discontinued[1][3][4][5][6].

Brand names

remacemide

Other names

remacemide hydrochloride(±)-2-amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride